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Abstract 
Several preclinical and some clinical studies have revealed that the mammalian target of rapamycin 
(mTOR) signaling pathway is involved in both genetic and acquired epilepsy syndromes.  
Excessive activation of mTOR signaling, as a consequence of loss-of-function of genes encoding 
for tuberous sclerosis complex (TSC) 1 and 2, is linked to the development of cortical 
malformations and epilepsy. This mTOR hyperactivation is associated with different epileptogenic 
conditions under the term of 'mTORopathies' such as tuberous sclerosis, focal cortical dysplasia, 
hemimegalencephaly and ganglioglioma. mTOR overactivation produces brain abnormalities that 
include dysplastic neurons, abnormal cortical organization and astrogliosis. mTOR inhibitors (e.g. 
rapamycin) have consistent protective effects in various genetic (e.g. TSC models and WAG/Rij 
rats) and acquired (e.g. kainate or pilocarpine post-status epilepticus) epilepsy animal models. 
Furthermore, clinical studies in patients with TSC and cortical dysplasia (CD) have confirmed the 
effectiveness of mTOR inhibitors also in epileptic patients. Therefore, mTOR is currently a very 
good candidate as a target for epilepsy and epileptogenesis. This review describes the relevance of 
the mTOR pathway to epileptogenesis and its potential as a therapeutic target in epilepsy treatment 
by presenting the most recent findings on mTOR inhibitors. 
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1. Introduction 
Epilepsy is a chronic neurological disorder characterized by recurrent seizures and caused by a 
large variety of genetic and acquired etiologies. Although many epilepsy patients are seizure-free 
when treated with drugs, about a third of patients remain still drug-resistant [1-3]. In addition, even 
when seizures are well controlled with antiepileptic drugs (AEDs), currently available drugs are 
only a symptomatic therapy in suppressing seizures (antiseizure or anticonvulsant) but do not have 
disease-modifying properties for preventing or reducing the development of epilepsy 
(antiepileptogenic) [4-6]. Therefore, novel treatments need to be searched to address both the 
problem of drugs-resistant epilepsy and the lack of disease modifying therapies. 
The mammalian target of rapamycin (mTOR) pathway regulates a number of important 
physiological functions and in the brain it is clearly involved in cell proliferation, growth and 
survival, protein synthesis, neuronal morphology and cortical development [7,8]; more recently, it 
has also been involved in the pathophysiology of several neurological diseases with particular 
attention to the epileptogenic process being indicated as a potential novel target for epilepsy 
treatments [9-12]. Dysregulation of the mTOR pathway has been involved in the development of 
different brain disorders that include focal cortical dysplasia (FCD), tuberous sclerosis complex 
(TSC), ganglioglioma and hemimegalencephaly, all potentially or certainly leading to epilepsy 
[9,13].  
Hyperactived mTOR seem to play a pivotal role in the pathogenesis of different animal models of 
acquired epilepsy, such as infantile spasms (IS), temporal lobe epilepsy (TLE), status epilepticus 
(SE), absence epilepsy, traumatic brain injury (TBI) and neonatal hypoxia–ischemia [11,14]. 
Accordingly, different studies have demonstrated that mTOR inhibitors, such as rapamycin and its 
analogues, decrease the development of seizures preventing epileptogenesis related mechanisms in 
many animal models and in some cases also some anticonvulsant activity has been evidenced 
[11,15,16]. From a clinical point of view, small trials have already indicated some kind of activity 
while larger controlled studies are ongoing using mTOR inhibitors (e.g. everolimus) in patients with 
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tuberous sclerosis complex and intractable epilepsy [17,18]. The importance of the mTOR pathway 
in epileptogenesis associated with tuberous sclerosis has been well demonstrated [19], while its role 
in epileptogenesis occurring in other forms of epilepsy remains to be better clarified and its 
potential as a target to be confirmed [20-22] 
Here, we review the most recent advances concerning the possible role of the mTOR signaling 
pathway in epilepsy and epileptogenesis, the preclinical studies of mTOR inhibitors treatment in 
different models of epilepsy, and the available clinical studies in patients with epilepsy.  
2. mTOR Pathways in Neurological Diseases 
The physiological regulation of the mTOR pathway is essential for normal cellular function; while, 
its dysregulation may promote the development/progression of disease under pathological 
conditions such as type 2 diabetes, inflammation, cancer, and cardiovascular disease [8,23,24]. 
Furthermore, abnormal mTOR signaling has been implicated in a variety of neurological disease 
[12,25].  
In the brain, mTOR mediates several processes involved in CNS development including 
neurogenesis, cell survival and migration, but it is involved in some other specific processes such as 
axonal sprouting, axonal regeneration and myelination, dendritic development and microtubule 
dynamics.  A direct role of mTOR in the modulation of glial functions has also been demonstrated 
[12,26,27]. The mTOR pathway is a key regulator during brain development, in fact, it participates 
in the control of protein expression and other cellular mechanisms including neuronal and glial 
differentiation, axon growth, navigation and synaptogenesis, all playing a role in neuronal 
excitability [28-30]. The mTOR pathway can influence neuronal excitability indirectly through 
mechanisms controlling synaptic structure and plasticity. In fact, Ras-PI3K-Akt-mTOR and Ras-
MAPK signaling pathways play an important role in the regulation of dendrite arborisation and 
spine formation, which are critical for the functioning of neurons and neuronal networks [28,29,31]. 
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Accordingly, mTOR pathway also affects neuronal excitability by modulating the expression of ion 
channels and receptors [32-35]. 
Considering the relevant role of this pathway in the brain, its dysregulation, such as loss-of-function 
gene mutations encoding for mTOR inhibitor proteins (e.g. TSC1, TSC2, PTEN), has been involved 
in neurological diseases such as epilepsy, Parkinson’s disease (PD), Alzheimer’s disease (AD), 
Huntington’s disease (HD) and brain traumatisms [11,12,36] but also psychiatric diseases such as 
depression, mental retardation, schizophrenia and cognitive impairment [37]. 
Recently, particular attention has been given to the role of mTORC1 in major depressive disorder 
(MDD) [38]. A post-mortem analysis of the prefrontal cortex (PFC) of subjects with MDD revealed 
deficits in mTOR signaling [39]. Furthermore, Chandran, et al. [40] showed that a chronic 
unpredictable stress (CUS) exposure produces deficits in mTOR signaling pathway in the 
amygdala. In agreement, chronic stress associated with depression induced by long-term 
corticosterone treatment causes an inhibition of the PI3K-Akt-TORC1 pathway [41]. These studies 
show an association between deficits in synaptic proteins and dysregulation of mTOR signaling in 
MDD and annulment of these abnormalities may underlie antidepressant activity. For example fast 
antidepressant response to ketamine, a NMDA receptor antagonist, seems be to mediate by 
activation of the mTOR pathway in the PFC of rats [42] and depressed patients [43]. 
Interestingly, abnormal mTOR signaling has also been implicated in diseases as fragile X syndrome 
[44], Down syndrome, [45] and Rett syndrome [46]. The potential involvement of dysregulated 
mTOR signaling in these neurological disorders characterized by cognitive deficits is likely linked 
to its role in physiological mechanisms of learning and memory [47]. In particular, mTOR plays an 
important role in the consolidation of memory through long-term potentiation (LTP) [33,48]. 
Furthermore, changes in dendritic morphology may represent a structural substrate for memory 
persistence and can be regulated by the mTOR pathway [28,29] whereas abnormalities in dendritic 
morphology have been demonstrated in many neurogenetic syndromes, including TSC, fragile X, 
Down and Rett [44,49]. 
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In contrast, other studies reported a relationship between enhanced mTORC1 activity and memory 
improvement; rapamycin seems to disrupt this process in several behavioral models including 
auditory fear conditioning and Morris water maze task [50,51]. Moreover, rapamycin 
administration decreased both spatial hippocampus memory and consolidation memory in many 
brain regions such as amygdala and hippocampus [50,52-54]. However, mTORC1 hyperactivity has 
been associated with memory deficits in human patients and experimental models of TSC [55]. In a 
mouse model of TSC, rapamycin rescued memory performance, which could be, at least in part, 
related to an abnormal mTOR activity [56].  The importance of mTOR signaling in CNS 
physiology is underscored by the several disorders in which mTOR pathway disruption is 
implicated, such as tumors, autism, mood disorders, neurodegenerative diseases as well as epilepsy 
[36,57,58].  
Finally, another link between mTOR and neurodegenerative diseases could be autophagy, which 
represents a catabolic process. It has been demonstrated how mTOR is a crucial regulator of 
autophagy [59]. A typical hallmark of neurodegenerative diseases, such as Alzheimer’s, 
Parkinson’s and Huntington’s diseases, is the aberrant accumulation of protein aggregates in the 
brain [60,61] and associated neuronal death. The clearance of these proteins would seem to be 
increased by mTOR inhibition [62,63]. Pharmacological manipulation of mTOR signaling is thus 
proving to be a promising therapeutic branch for the treatment of several neurological disorders 
[57].  
 
3. Role of mTOR pathway in epilepsy and epileptogenesis 
Considering mTOR involvement in cellular functions influencing neuronal excitability, it is not 
surprising that this signaling pathway can be responsible for or participate to the development of 
spontaneous seizures, and that this pathway could represent an important target for both 
epileptogenesis and seizure pharmacotherapy [11,20,64]. Since early 2000, many preclinical and 
some clinical data have underscored the importance of mTOR pathway in both genetic and acquired 
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epilepsy syndromes [65]. Excessive activation of mTOR signaling, as a consequence of loss-of-
function mutations of genes encoding for natural mTOR inhibitors such as TSC1 and TSC2 (coding 
for the proteins hamartin and tuberin, respectively), phosphatase and tensin homolog (PTEN) and 
STE20-related kinase adaptor alpha (STRADalpha), are linked both to the development of cortical 
malformations and epilepsy. These malformations or "mTORopathies"-related epilepsies include: 
hemimegalencephaly, ganglioglioma, focal cortical dysplasia (FCD), and tuberous sclerosis 
complex (TSC) [13,66].  
The term "mTORpathies" describes neurological disorders characterized by altered cortical 
architecture, abnormal neuronal morphology and intractable epilepsy as a consequence of excessive 
mTOR signaling, providing a likely histopathological substrate for epileptogenesis [14,67]. On the 
other hand, seizures themselves, in the absence of any other associated pathology, may directly 
cause activation of mTORC1 activity [20]. Many experimental models of genetic and acquired 
epilepsy, in which mTOR hyperactivation was present, are responsive to mTOR inhibitors [15,16]. 
Rapamycin and other mTOR inhibitors decrease seizures, delay seizure development, or prevent 
epileptogenesis in many experimental models [65]. This evidence supports the hypothesis that 
dysregulation of the mTOR pathway seems to be a key condition for the development of 
epileptogenesis and epilepsy. To date, the mechanisms by which mTOR inhibition gives rise to the 
inhibition of seizure activity in several experimental models is still unclear. Nevertheless, the use of 
selective mTOR inhibitors can represent an important new therapeutic strategy for managing or 
eventually preventing epilepsy due to these disorders [9].   
 
3.1 Preclinical Studies 
Dysfunction of mTOR signaling pathway is involved in the pathophysiology of Tuberous sclerosis 
complex (TSC) [68]. However, this dysfunction also plays an important role during the latent phase 
of epileptogenesis of some acquired forms of epilepsy, such as temporal lobe epilepsy (TLE), 
traumatic brain injury (TBI) [69], infantile spams (IS) [70] and neonatal hypoxia–ischemia [71].  
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3.1.1 Tuberous sclerosis complex models 
Among the genetic epilepsy syndromes, TSC has drawn particular attention, since it is strongly 
linked with the dysregulation of the mTOR pathway [10]. TSC is an inherited autosomal disorder 
resulting from a mutation of one of two tumor suppressor genes: TSC1 and TSC2 [72]. In TSC, 
benign tumors may develop in multiple organs such as skin, liver, heart, kidney, lung and the brain, 
in which it is often associated with the development of subependymal giant cell astrocytoma 
(SEGA) among other tumors [73]. Unfortunately, many TSC patients suffer of drug-resistant 
epilepsy [74-76]. mTOR dysregulation in TSC directly affects many downstream mechanisms, 
including alteration of neurotransmitter receptors and ion channel expression, and synaptic and 
neuronal organization, leading to epileptogenesis process [15,77]. In the context of TSC-associated 
epilepsy, aberrant mTOR signaling has been repeatedly demonstrated, and conditional knockout of 
TSC1 or TSC2 in various brain cell populations has been associated with elevated levels of mTOR 
signaling and seizures in several transgenic mouse models [78,79]. Animal models of TSC are 
crucial to study the link between mTOR, TSC and epilepsy [80,81]. Mice with TSC1 or TSC2 
deleted, in specific neural populations (astrocytes or neurons), show neuropathological phenotypes 
(i.e. astrogliosis, neuronal autophagy, macrocephaly, seizures and premature death) similar to those 
found in human TSC [78,82].  
Clinical and pre-clinical studies, using mTOR inhibitors (i.e. rapamycin and everolimus) 
demonstrated the role of mTOR in TSC-associated epilepsy [83,84]. Inhibition of mTOR signaling 
by rapamycin in a mouse model of TSC with conditional inactivation of the Tsc1 gene primarily in 
glia (Tsc1GFAPCKO mice) can prevent astrogliosis, neuronal disorganization and seizures early in 
the course of the disease, suggesting that the aberrant mTOR activation interferes with normal brain 
function and leads to epilepsy [85]. Similarly, using a knock-out mouse model of TSC in which 
Tsc1 was ablated in most neurons during cortical development, rapamycin treatment and its derivate 
everolimus were able to reverse the animal phenotype, rescuing the mutants from epilepsy [86]. 
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Early treatment with rapamycin in Tsc2GFAP1CKO mice, also rescued the mutants from epilepsy and 
increased their survival [87,88].  Rapamycin seems effective not only reducing seizures once they 
start but also in preventing seizures from ever developing as well as many of the pathological and 
molecular changes (as progressive astrogliosis, inflammatory mechanisms, hippocampal 
neurodegeneration, brain hypercellularity) in the brain that likely promote epileptogenesis in these 
mice; this indicates that mTOR may have an anti-epileptogenic effect in these genetic models 
[85,86,88]. However, following discontinuation of rapamycin therapy, these phenotypes at least 
partially return and are accompanied by progressive development of severe seizures and early 
death. Inflammatory signaling mechanisms, particularly the cytokine IL-1β and chemokine 
CXCL10, are abnormally activated in Tsc1GFAPCKO mice; these inflammatory mediators were 
reversed by rapamycin treatment, indicating that cytokine and chemokine signaling is downstream 
from mTORC1 and occurred in astrocyte culture in vitro and before epilepsy onset in vivo [89]. 
Recently, it has been reported a primary role for TORC1 signaling in epileptogenesis, using mice 
with biallelic Tsc1 deletion; this latter resulted in activation of TORC1, enhanced neuronal 
excitability and epilepsy development without any obvious histological changes. Increased TORC1 
activation appears sufficient for the development of epilepsy, even in the absence of changes in 
brain pathology. Rapamycin treatment reduced TORC1 activity, seizure frequency and increased 
survival indicating an important role of mTOR for managing seizures not only in the presence of 
major brain pathology but also in other type of epilepsies that result from increased mTOR 
hyperactivation [90]. Among current AEDs, vigabatrin (VGB) has been shown to have unique 
efficacy in partial seizures related to TSC and infantile spasms [91] and early treatment, even before 
seizure onset, can improve the long-term outcome of epilepsy in patients with TSC [92,93]. To date, 
the exact mechanism by which VGB is effective in TSC remains unclear. In addition to its already 
proven mechanism of action to increase brain γ-aminobutyric acid (GABA) levels by inhibition of 
γ-aminobutyrate transaminase (GABA-T) [94], VGB also seems to inhibit mTOR pathway in the 
neocortex and hippocampus of TSC1GFAPconditional knockout mice, providing a possible 
 10 
explanation for the unique effectiveness of this drug in TSC [95]. Therefore, VGB seems to also 
directly act on the mTOR pathway; however, an indirect action cannot yet be excluded. 
Furthermore, it was reported that a prophylactic antiepileptic treatment of  TSC patients (and at 
high risk of epilepsy) with VGB, but also levetiracetam, valproic acid and topiramate, markedly 
improved their risk of developing mental retardation and reduced the incidence of drug-resistant 
seizures [92,93] (Table 1 and 2). 
3.1.2 Cortical dysplasia models 
Similar to TSC, several other, relatively rare genetic disorders entangle a dysregulation of the 
mTOR pathway and an increased risk for tumors and epilepsy. Brain-specific deletion of the mouse 
homolog PTEN, an upstream activator of the mTOR pathway [96], mimics several features of 
human cortical dysplasia (CD), including neuronal hypertrophy, cortical and hippocampal 
disorganization, aberrant mossy fiber sprouting and epilepsy [19]. CD (also known as malformation 
of cortical development) is another recognized type of "mTORpathies" characterized by intractable 
epilepsy in which mTOR dysregulation plays a key role in determining epilepsy phenotype [97]. 
Since CD has been linked to mutations of genes encoding for mTOR regulators [68], mTOR 
inhibitors through their antiepileptogenic mechanisms might be useful for the treatment of the CD-
related epilepsy [98,99]. Recently, a link in CD between the up-regulated miRNAs (i.e.hsa-miR-21 
and hsa-miR-155) and mTOR pathway has been evidenced [100]. Furthermore, PTEN deficiency is 
linked with the excessive growth, migration and proliferation of dysplastic cells in CD [101]. To 
better understand the role of mTOR in CD and epilepsy, Ljungberg, et al. [102] have characterized 
neuron subset-specific Pten knockout (NS-Pten KO) mice as an experimental model of CD. Pten 
knock-out mice exhibit neuronal hypertrophy, megalencephaly and seizures as a consequence of 
enhanced mTOR activity, and both early and later treatment with rapamycin decreases pathological 
abnormalities, suppresses the development of seizures and reduces established late-stage epilepsy 
[102]. Rapamycin treatment, at late stages of the pathology, decreased mTORC signaling, 
astrogliosis and microgliosis that were found in NS-Pten KO mice of CD [103]. Treatment with 
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mTOR inhibitors also reverses the neuronal hypertrophy and megalencephaly in PTEN knock-out 
mice [104,105]. Similar to the TSC models, seizures return with the cessation of rapamycin 
treatment, although intermittent rapamycin treatment is able to maintain a long‑term antiseizure 
effect [104] (Table 2). 
 
 
 
3.1.3 Temporal lobe epilepsy models 
PTEN inactivation, in human and animals hippocampal dentate granule cells, induces the 
development of abnormal granule cells and spontaneous seizures similar to temporal lobe epilepsy 
(TLE) [31]. During epileptogenesis, adult-generated dentate granule cells (DGCs) form aberrant 
neuronal connections with neighboring DGCs increase neuronal excitability in the hippocampus. 
Sutula and Dudek [106] demonstrated that PTEN deletion among hippocampal granule cells was 
sufficient to develop spontaneous seizures in a few weeks, and that mTOR signaling played a 
fundamental role in this process. Therefore, hyperactivation of the mTOR pathway as a result of 
PTEN deletion is a possible mechanism of epileptogenesis also in TLE. Moreover, rapamycin 
administration was effective in inhibiting epileptogenesis and presence of abnormal granule cells in 
this PTEN animal model [31]. mTOR inhibitors can decrease pathological abnormalities that are 
associated with epileptogenesis, in particular mossy fiber sprouting [20,107,108]. Accordingly, it 
was demonstrated that mTOR inhibitors rescued fiber sprouting by promoting the survival of the 
somatostatin/green fluorescent protein (GFP)-positive interneurons after pilocarpine-induced status 
epilepticus (SE) in mice [109]. Some studies report that rapamycin is also able to decrease both 
epileptiform activity and mossy fiber sprouting in mouse models of TLE such as pilocarpine and 
kainate-post SE spontaneous seizures [107]. Furthermore, rapamycin acts on axonal sprouting and 
is able to revert abnormal cell growth [19]. However, other studies have shown that rapamycin 
treatment induced reduction of mossy fiber sprouting but not the frequency of pilocarpine-induced 
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spontaneous seizures in mice [107,110]. In addition to mossy fiber sprouting, rapamycin treatment 
reversed neuronal death and neurogenesis that contribute to epileptogenesis, but these data are 
controversial [20]. Different studies demonstrated that the mTOR pathway is markedly enhanced, in 
a biphasic manner, after kainate-induced SE in both hippocampus and cortex. The exact mechanism 
by which kainate induces this mTOR enhancement is unclear. However, it was hypothesized that 
excessive release of glutamate could be involved in this process [111,112]. Administration of 
rapamycin, prior or after kainate-induced SE, blocked cell death, neurogenesis, mossy fiber 
sprouting, and the reduced spontaneous epilepsy in this mouse model of TLE [20,108]. Similar 
results were obtained in the pilocarpine-SE model [113]. Accordingly, the authors claimed that the 
mTOR pathway mediates mechanisms of epileptogenesis in kainate and pilocarpine rat models and 
rapamycin could have anti-epileptogenic effects in these models [20,106,114,115]. However, 
paradoxical effects of mTOR inhibition have also been reported. In fact, mTOR activation can have 
both pro-apoptotic and anti-apoptotic effects, depending on different phases of the cell cycle [116]. 
Rapamycin administration within 1 hour of kainate injection in rats, induced enhancement of the 
mTOR pathway, higher than with kainate alone, whereas when rapamycin was administered after 
this time period, the expected inhibition was observed [117]. Therefore, mTOR would seem to act 
as a master switch that regulates, under different situations, neuronal death and epileptogenesis. It 
was reported that post-treatment with rapamycin after amygdala electrical stimulation-induced SE, 
did not stop the epileptogenic process and did not decrease disease severity. These data suggest that 
the antiepileptogenic effects of mTOR inhibition are not universal within animal models and may 
depend on several variables [22,110].  In agreement, rapamycin treatment started after electrically 
induced SE, reduced the development of recurrent spontaneous seizures. Likewise, rapamycin 
reduced other potential features related to epilepsy and epileptogenesis, such SE-induced neuronal 
cell loss, mossy fiber sprouting, and blood–brain barrier (BBB) albumin leakage; however, it did 
not reduce hippocampal microglia or astrocyte activation indicating only partial effects [118].  
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Very recently, it has been reported that rapamycin treatment after kainic acid–induced SE 
influences BBB leakage. Moreover, rapamycin is not able to reduce the seizure onset through an 
improvement of the BBB during the early phase of epileptogenesis. At odds, it is able to reduce 
BBB leakage during the chronic phase decreasing: gliosis, brain inflammation and angiogenesis. 
These effects could be related to the inhibitory properties of rapamycin on the development of 
epilepsy [119,120] (Table 1 and 2). Finally, mTOR activation in astrocytes contributes to TLE and 
may be targeted to suppress astrogliosis and spontaneous seizure [121]. 
 
3.1.4 Other models of epileptogenesis 
Recently, mTOR overactivation has been also shown in an animal model of absence epilepsy (the 
WAG/Rij rat), suggesting that this mechanism might be a very common pathological component for 
epileptogenesis in different models of epilepsy [122]. It was also established that WAG/Rij rats, a 
well-validated genetic model of absence epilepsy, epileptogenesis and mild-depression comorbidity 
[123-125], have higher levels of total mTOR in several brain areas, including the cortex, 
hippocampus and thalamus in comparison to Wistar rats, [126]. Inhibition of mTOR by rapamycin 
(started before seizure onset; i.e. at postnatal day 45) permanently reduces the development of 
spontaneous absence seizures in this model. In addition, WAG/Rij rats in comparison to Wistar rats 
also showed an age-related decline in hippocampal neural progenitor cell proliferation rate, 
suggesting that mTORC1 overexpression might be one of the triggers of epileptogenesis [122,126]. 
Rapamycin effects in this model have been linked to a modulation of inflammatory 
responses/alterations following its administration; rapamycin would block the lipopolysaccharide 
dependent increase in pro-inflammatory cytokines in the brain [127]. 
The mTOR pathway is also activated by hypoxia or toxin-related insults that acutely induce 
neonatal seizures or infantile spasms [70,128]. In hypoxia-induced neonatal seizures in rodents, 
activation of mTORC1 pathway was associated with the induction of seizures in the immature rat 
brain; rapamycin treatment immediately before and after seizures reversed early increases in 
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glutamate neurotransmission and seizure susceptibility attenuating later life epilepsy and autistic-
like behavior [128]. Rapamycin treatment suppresses infantile spasms (IS) permanently and 
improve cognitive outcome; the suppression of spasms was correlated with the ability of rapamycin 
to normalize TORC1 activity in perilesional cortical neurons [70].  
In a rat model of cryptogenic infantile spasms, in which seizures were triggered by N-mehtyl-D-
aspartate (NMDA), pretreatment with VGB, but not rapamycin in low doses, suppressed IS [129]. 
While genetic epilepsies affecting the mTOR pathway are relatively rare, there is increasing interest 
as to whether the mTOR pathway may be involved in other, more common types of epilepsy, such 
as following acquired brain injury. Traumatic brain injury (TBI) is a major cause of death, mental 
diseases and disability. Among the consequences, TBI post-traumatic epilepsy is very common and 
is a cause of significant morbidity and mortality in TBI patients [130]. Akt and mTORC1 activation 
have been highlighted in a number of traumatic brain injury (TBI) models [131,132]. Studies have 
reported that mTOR inhibitors might have antiepileptogenic effects in the development of post-
traumatic epilepsy in an animal model of TBI [69]. Rapamycin injection 4h following closed head 
injury significantly improved functional recovery. In rodent models of TBI, mTOR inhibition 
reduced neuronal death and mossy fibers sprouting and, as a result, improved cognitive outcome 
[133]. Rapamycin was tested in an experimental model of controlled cortical impact (CCI) injury, a 
well-validated model of TBI, in which has also been proven that an aberrant activation of mTORC1 
occurs. Rapamycin administration, started after CCI, had no effect on acute symptomatic seizures, 
but significantly prevented the development of chronic post-traumatic epilepsy [134]. mTOR 
involvement in TBI has also been demonstrated in a rat hippocampal organotypic culture model of 
post-traumatic epilepsy. Ictal activity was measured both by lactate production and by multiple 
electrode array (MEA) recordings (Table 1 and 2).  
 
Table 1.  Preclinical evidence on the role of mTOR inhibitors in preventing epileptogenesis 
Epilepsy Type/ 
AnimalModel 
mTOR 
inhibitor and 
Protocol of 
Administration 
Effect of mTOR 
inhibitor  on epilepsy 
Hypothesized 
Mechanism(s) of 
References 
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dose development Action 
Genetic epilepsy 
(Tuberous sclerosis)  
Tsc1GFAPCKO mice 
 
Rapamycin 
3 mg/Kg i.p. 
Postnatal day 14 
(~2 weeks 
presymptomatic) 
 
Late treatment 
started at 6 weeks 
of age  (P42) after 
onset of 
neurological 
abnormalities  
Inhibition of epilepsy 
development; prolonged 
survival during 
treatment 
 
 
Delay in 
onset, decrease in 
frequency and duration 
of seizure. 
Inhibited abnormal 
activation of mTOR, 
astrogliosis, neuronal 
disorganization and 
increased brain size.  
[85] 
 
Genetic epilepsy 
(Tuberous sclerosis) 
Tsc2GFAP1 CKO mice 
Rapamycin 
3 mg/kg i.p. 
Treatment started 
at P14, 5 
days/week, up to 
the end of 
experiments 
 
Rescued the animals 
from epilepsy and 
increased their survival 
Inhibited astrogliosis, 
neuronal 
disorganization and 
increased brain size. 
Reduced  levels of 
phospho-S6 
[88] 
 
Genetic epilepsy 
(Tuberous sclerosis) 
Tsc1GFAP1CKO mice 
Rapamycin 
1 mg/kg for 3 d 
each week 
Treatment started 
at P8 
No seizures developed; 
prolonged 
survival during 
treatment 
Reversed Neuronal 
Dendritic 
abnormalities, ER 
Stress 
[87] 
 
Genetic epilepsy 
(Tuberous sclerosis) 
Tsc1null-neuron mice 
 
Rapamycin and  
Everolimus 
6 mg/kg i.p. 
Treatment started 
at P7-P9, every 
other day, up to 
92 days (P100) 
 
Prolonged survival, 
prevention of  
spontaneous seizures 
during treatment 
 
Improved 
neurofilament 
abnormalities, 
myelination, and cell 
enlargement. Reduced  
levels of phospho-S6 
[86] 
 
Genetic epilepsy 
(cortical dysplasia) 
 Pten GFAP KO 
 
Rapamycin 
10 mg/kg i.p. 
Treatment (2 
weeks) started at 
the 4th and 5th  
weeks; postsymptoms 
Reduced the severity 
and the duration of the 
seizure activity, 
persisted following 
discontinuation of 
treatment  
Hypothesized changes 
in subcellular 
structures and, 
possibly, in processes 
that are involved in 
synaptic plasticity and 
membrane excitability 
[135]  
 
Genetic epilepsy 
(Cortical dysplasia) 
NSE-Pten CKO mice 
Rapamycin 
10 mg/kg i.p. 
Treatment started 
in mice of 5–6 
weeks old 
(presymptomatic 
phase) 
 
Decreased seizure 
duration and frequency 
Inhibition of 
anatomical, cellular 
and behavioural 
abnormalities related 
with mTOR pathway 
hyperactivation 
[105] 
 
Genetic epilepsy 
Pten KO mice 
 
Rapamycin 
6mg/kg/day i.p. 
Treatment started 
2-5 days post 
tamoxifen 
injection 
Reduced seizures Inhibited mossy fibre 
sprouting 
[31] 
 
Acquired epilepsy 
(TLE) 
Kainic-acid induced 
SE  
Rapamycin 
6mg/kg/day i.p. 
Treatment started  
3 days before SE 
or 24 h after 
SE, up to 7 
weeks. 
Suppressed the 
development of seizures 
 
Blocked cell death, 
neurogenesis, mossy 
fibre sprouting 
[20] 
 
Acquired epilepsy 
(TLE)  
Pilocarpine-induced 
SE 
 
Rapamycin 
3mg/kg/day i.p. 
Treatment started 
24 h after SE for 
2 months 
Blocked mossy fibre 
sprouting. No effects on 
seizure frequency 
Inhibition of mossy 
fiber sprouting 
[107,109,110] 
Acquired epilepsy 
(TLE) 
Amygdala 
stimulation-induced 
Rapamycin 
6 mg/kg daily 
Treatment started 
24 h after SE for 
2 weeks 
Did not stop the 
epileptogenic process 
and no decrease in 
disease severity 
No effect on mossy 
fiber sprouting 
[22] 
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SE 
Acquired epilepsy 
(TLE) 
Pilocarpine induced 
SE in mice 
Rapamycin  
6 mg/kg daily 
Treatment started 
24 h after the 
onset of SE for 6 
consecutive days 
Suppressed epileptiform 
activity 
inhibited mTOR 
pathway and 
repressing mossy fiber 
sprouting 
[114]  
 
Acquired epilepsy 
(TLE)  
Electrical stimulation 
of the angular bundle 
(SE) 
 
Rapamycin 
6 mg/kg/day i.p. 
Treatment for 7 
days, started 4 
hours after the 
induction of SE, 
and continued 
until rats were 
sacrificed, 6 
weeks after SE. 
 
Reduced the 
development of epilepsy 
 
 
Inhibition of mossy 
fiber sprouting, 
reduction in neuronal 
death, decreased 
BBB leakage; 
no reduction of 
inflammatory 
response after SE 
induction 
[118] 
 
Acquired epilepsy 
(TLE)  
kainic acid–induced 
SE 
Rapamycin 
6 mg/kg/day 
Treatment  started 
4 h after SE, once 
daily for 7 days, 
and continued 
until rats were 
killed 7 weeks 
post-SE. 
reduction or prevention 
of recurrent seizures 
at a later stage. 
Reduced BBB leakage 
during the chronic 
phase, via reduction 
of gliosis, brain 
inflammation and angiogenesis. 
[119,120]   
Acquired epilepsy  
TBI 
 
Rapamycin 
6 mg/kg/day i.p. 
Treatment started 
1 hour after injury 
and continued for 
1 month 
Prevented the 
development of post-
traumatic epilepsy 
Decreased neuronal 
degeneration and 
mossy fibre sprouting, 
although this effect 
did not directly 
correlate with 
inhibition of 
epileptogenesis 
[134,136]  
 
Acquired epilepsy 
Hypoxia-induced 
seizures in rats 
Rapamycin  
3 mg/kg i.p. 
Treatment started 
24 h before and 1 
h 
after exposure to 
hypoxia 
No effect on acute 
seizures; decreased 
chronic seizures 
inhibited mTORC1 
pathway, and 
subsequent increased 
glutamatergic 
neurotransmission. 
[128] 
Absence epilepsy 
model WAG/Rij rats  
 
Rapamycin 
1 mg/kg os 
Treatment started 
at P45 and 
continued for 17 
weeks 
Decreased the 
development of absence 
seizures 
inhibition of the 
release of 
inflammatory 
cytokines 
[122,126] 
SE = Status Epilepticus; TLE = Temporal Lobe Epilepsy; BBB = Blood Brain Barrier; CKO = Conditional Knockout; GFAP = 
Glial Fibrillary Acid Protein; i.p. = intraperitoneally; KO = Knockout; NS-Pten KO = Neurone Subset-Specific Pten knockout; NSE 
= Neuron-Specific Enolase; P = Postnatal day; PTEN = Phosphatase and Tensin homolog; TBI = Traumatic Brain Injury; TSC 1 = 
Tuberous Sclerosis Complex 1; TSC 2 = Tuberous Sclerosis Complex 2; WAG/Rij rat  = Wistar Albino Glaxo/Rij-rat. 
 
 
Table 2.  Preclinical evidence on the role of mTOR inhibitors in preventing seizures 
Epilepsy 
Type/Model 
mTOR 
inhibitor and 
dose 
Protocol of 
Administration 
Effect of mTOR 
inhibitor on 
Seizures 
Hypothesized 
Mechanism(s) of Action 
References 
Genetic epilepsy 
NS-Pten KO 
(cortical dysplasia) 
 
Rapamycin 
10 mg/kg i.p. 
Intermittent 
treatments (over a 
period of 5 months) 
 
Decreased seizures 
and improved 
survival after 
additional 
intermittent 
treatments 
Changes in subcellular 
structures and, possibly, in 
processes involved in 
synaptic plasticity and 
membrane excitability  
[102,104] 
 
 
Genetic epilepsy  
NS-Pten KO mice 
(cortical dysplasia)
  
Rapamycin 
10 mg/kg/day 
i.p. 
Treatment started 
at P9 
Attenuated 
epileptiform activity  
Suppressed  mTOR 
hyperactivation; 
Reduced astrogliosis and 
microgliosis 
[103] 
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Genetic epilepsy 
Pten GFAP KO 
Temsirolimus 
7.5 mg/kg 
Treatment started 
from 6 to 16 weeks, 
when mutant mice 
were symptomatic 
Decreased seizures 
and mortality  
Decreased megalencephaly, 
cell size 
[101] 
 
Genetic epilepsy 
Acute biallelic 
deletion of Tsc1 in 
adult mice 
Rapamycin 
5 and 10 
mg/kg/day 
i.p. 
Treatment started 
2–4 months post-
natal 
Prolonged survival; 
No seizures 
developed during 
treatment 
Effectively reduced pS6 
levels 
[90] 
 
Epileptic 
encephalopathy 
Multiple-hit rat 
model of infantile 
spasms 
Rapamycin 
different 
doses 
After the onset of 
spasms. 
 
Reduction of  
acutely-induced 
spasms in a dose-
related way 
Unclear 
 
[70]  
TLE following 
Pilocarpine- 
induced 
SE in adult rats 
Rapamycin 
5mg/kg/day 
i.p. 
Pre-treatment for 3 
days before the 
induction of 
seizures with 
pilocarpine 
Reduction seizure 
activity during 
treatment, gradually 
returning after 
discontinuing 
treatment 
Suppressed mossy fiber 
sprouting 
[108] 
 
Acquired epilepsy 
Acute seizure 
models in 
Sprague-Dawley 
rats 
Rapamycin 
5 mg/kg i.p. 
Treatment started, 
in immature and 
mature rats, prior to 
induction of 
seizures by PTZ, 
pilocarpine or 
kainate 
Increased severity of 
seizures; decreased 
seizure threshold 
after 3 daily doses of 
rapamycin in 3–4 
weeks old, but not 
adult, rats 
Treatment down-regulates  
KCC2 expression in CNS, 
which could increase 
susceptibility to pilocarpine-
induce seizures in immature 
rats 
 
 
[32] 
Epileptic 
encephalopathy 
Infantile spasms in 
rats prenatally 
treated with 
betamethasone, 
triggered with 
NMDA 
Rapamycin 
3 mg/kg i.p. 
Pre-treatment 
24h prior to 
induction of 
spasms 
No effects in this 
model 
 [129] 
 
 
Acquired epilepsy 
Acute seizure 
models in 
Sprague-Dawley 
rats acute seizure 
tests  
 
Rapamycin  
3 or 6 mg/kg 
i.p. 
Used different 
treatment paradigm 
in  rat pups (P15) 
and juvenile (P55–
60) rats 
Variable efficacy on 
acute seizures which 
are age, time, 
treatment paradigm 
and model 
dependent. 
 
The lack of effects, above all 
in immature rats, has been 
correlated with decreased 
NPY expression in the 
cortex and hippocampus 
[115] 
Acquired epilepsy  
Multiple Acute 
seizure (6Hz, PTZ 
or kainate) tests in 
NIH Swiss mice
  
 
Rapamycin  
4.5 mg/kg i.p. 
Short-term 
treatment (single 
dose) 3h before 
seizure onset and 
long-term treatment 
(3 daily doses) 
before seizure 
onset 
Variable efficacy on 
acute seizures, which 
are age, time, 
treatment paradigm 
and model- 
dependent 
Reduction in neuronal 
excitability and/or 
neurotransmitter release may 
occur with rapamycin 
[137] 
 
CNS = Central Nervous System; GFAP = Glial Fibrillary Acid Protein; i.p. = intraperitoneally; KCC2 = Potassium Chloride 
Cotransporter 2; KO = Knockout; mTOR = mammalian Target Of Rapamycin; NPY = Neuropeptide Y; NS-Pten KO = Neurone 
Subset-Specific Pten knockout; P = Postnatal day; pS6 = Phospho-S6; PTEN = Phosphatase and Tensin homolog; PTZ = 
Pentylenetetrazole; TSC 1 = Tuberous Sclerosis Complex 1; TSC 2 = Tuberous Sclerosis Complex 2;  
 
3.2 Clinical studies 
Despite the current pharmacological and non-pharmacological treatment options, about a third of 
the epileptic patients remain drug-resistant [138,139]. Indeed, TSC is also characterized by 
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pharmacologically uncontrolled seizures. The United States Food and Drug Administration (FDA) 
approved everolimus, a rapamycin analogue, for the treatment of patients with TSC associated with 
inoperable SEGAs [17,140].  Beneficial effects of mTOR inhibition with everolimus have been 
reported previously in patients with TSC and epilepsy [74,141-143]. Therefore mTOR inhibitors 
provide a potential therapy based on the pathophysiology of TSC [77].  
In 2009, it has been described for the first time that rapamycin treatment (10 months) induced a 
reduction in seizure frequency and severity in a 10-year-old girl with difficult-to-treat seizures in 
TSC, although pre- and post-treatment magnetic resonance imaging did not reveal any change in the 
cortical tubers [144]. In another study, a child treated with everolimus for a regrowing SEGA, a 
complete cessation of previously intractable seizures was reported at 12 months follow-up [18].  
Everolimus treatment improved seizure control in prospective phase I/II studies in patients with 
TSC [141] and in patients with TSC and associated SEGA [74]. In one of these studies (prospective 
open label phase I/II study), Krueger, et al. [74] showed that everolimus used in TSC to limit SEGA 
(associated with TSC) (primary end point), decreases seizure frequency in approximately 60% of 
patients studied (secondary end point), but 1 patient experienced increased seizure frequency with 
the drug [74,145]. In particular, 9 out of 16 patients with TSC showed a decrease in seizure 
frequency, 6 did not show significant reduction, whereas in 1 an increased seizure frequency was 
noted. The effect of everolimus, after 12 weeks of treatment in the management of 
pharmacoresistant epilepsy in patients > 2 years affected by SEGAs, was also investigated in a 
prospective, multicentre, open-label, phase I/II clinical trial [141]. The study compared seizure data 
during the last 4 weeks of everolimus treatment (weeks 13–16) with the 4-weeks period before 
everolimus initiation (baseline, weeks 1–4). 
Everolimus treatment (12 weeks) in pediatric patients with TSC and refractory epilepsy reduced 
seizure frequency by a median reduction of 73% in 17 of 20 patients examined and a median 70% 
decrease in cumulative seizure duration. Four of these patients were seizure-free at 12 weeks, and 
seven had a 90% reduction in seizure frequency [141]. Everolimus was well tolerated; all adverse 
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events were mostly grade 1 or 2 in severity and usually transient, never requiring everolimus 
withdrawal. Upper respiratory infections, stomatitis and mucositis were the most common adverse 
events [141]. Therefore, these findings strongly suggest that everolimus might be an effective 
treatment for SEGA-related epilepsy. The different animal studies and limited clinical data have led 
to further current clinical trials for inhibition of mTOR in genetic epilepsies. A compassionate use 
trial for seven TSC patients with drug resistant epilepsy has demonstrated the efficacy of 
everolimus; one patient discontinued treatment because of rash, four of six patients exhibited a 
reduction of seizure frequency of 25-100%, two of six 6 patients, did not show alteration of seizure 
frequency. Everolimus treatment seemed to be well-tolerated with adverse effects similar to those 
reported in previous studies [143]. 
Recently, an open-label case series in seven patients (median age 6 years), with TSC and refractory 
epilepsy, described the efficacy mTOR inhibitors (six with rapamycin and one with everolimus), in 
seizures improvement, which were reported to have only minimal adverse effects. Of the intractable 
seizure group (7 patients), 1 patient had >90% reduction, 4 had 50%-90% reduction, and 2 had 
<50% reduction. Moreover, this treatment was reported to improve other characteristics of TSC, 
such as facial angiofibromas and cognition; three reported subjective improvements in learning 
[146]. Recently, another single case of seizures aggravation after everolimus treatment for SEGA 
has been reported [147]. Cessation of seizures or a reduction in seizure frequency was also reported 
in a small number of pediatric patients with TSC who were treated with long-term everolimus.  In 6 
out of 8 children, at least a 50% reduction in SEGA volume was observed; everolimus resulted in 
permanent seizure cessation in one child with severe drug-resistant epilepsy and in at least a 50% 
reduction in the number of seizures in two other [142].  
Moreover, in a prospective study of 5 neonatal patients with TSC, it was demonstrated that EEG 
changes occurring in TSC patients before clinical seizures reflect the process of epileptogenesis in 
these patients. Therefore, EEG recording could have predictive value during infancy in patients 
with TSC [148].  
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More recently, the case of a 13-year-old girl with TSC-associated with refractory generalized 
seizures who initiated treatment with everolimus experiencing subsequent improvement in several 
TSC manifestations, including a reduction in seizure frequency from clusters of two or three daily 
to one every 2 to 4 weeks after 1.5 years of treatment was described [149]. All these clinical studies 
confirm the potential benefits of mTOR inhibitors on epilepsy associated with TSC, but the open-
label design of the studies as well as the heterogeneity of enrolled patients and the small number of 
cases still does not allow making definite conclusions. 
A randomized, blinded, placebo controlled, phase III trial is currently in progress to determine the 
efficacy of everolimus on seizures in patients with TSC; patients between the ages of 2 and 65 
years, with a clinically definite diagnosis of TSC and uncontrolled partial-onset seizures, are 
currently being enrolled for this study and results are expected during the next year 
(clinicaltrials.gov identifier NCT01713946) (Table 3). 
Recently, a genomics study of infantile spasms and Lennox-Gastaut Syndrome has found a de novo 
mutation in mTOR gene without associated brain malformations suggesting a possible role of 
mTOR in these disorders and mTOR inhibitors could be a possible treatment [150]. Furthermore, de 
novo somatic mutations of PI3K, AKT3 or mTOR genes in patients with hemimegalencephaly 
(HME) a condition associated with resistant epilepsy have been described [31,151].  
 
 
Table 3.  Clinical Studies with mTOR Inhibitors in TSC-Associated Epilepsy 
Type of Study  Disease Drug 
and Dose 
Number and 
Age of 
Patient(s)  
Duration of 
Treatment 
Clinical Result  References 
Case report TSC and 
refractory 
epilepsy 
Rapamycin 
0.15 mg/kg/day 
1 patient; 
9-year-old girl 
10 months Reduction in seizure 
frequency. 1 to 5 brief 
seizures (< 2 minutes) 
continued daily 
[144] 
Case report TSC and 
refractory 
epilepsy 
Everolimus 
4.5 mg/m2/day 
1 patient; 
10- year-old boy 
12 months Complete cessation of 
epileptic seizures 
[18] 
 
Prospective, 
open-label, 
phase I–II study 
TSC and 
related 
epilepsy 
Everolimus  
4.7–5.6 
mg/m2/day 
 
 
16 patients; 
3 year-old or 
older 
 
 
Median 
duration  
21.5 months 
(range: 4.7-
34.4 months)  
 
Reduction in seizure 
frequency in 9/16 
patients, did not change 
in 6, and increased in 1 
[74] 
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Prospective, 
multicenter, 
open-label, 
phase I/II 
clinical trial 
TSC and 
refractory 
epilepsy 
Everolimus  
5 mg/m2/day,  
then titrated to a 
serum trough 
level of 5–15 
ng/ml 
20 patients; 
median age:8 
years 
(age range:2–
21) 
12 weeks Reduction in seizure 
frequency in 17/20 
patients (median 
reduction of 73%).  
4 of these patients were 
seizure-free at 12 
weeks, and 7 had a 90%  
reduction in seizure 
frequency 
[17,141] 
 
Case study 
series 
TSC and 
refractory 
epilepsy 
Everolimus 
5-7 mg/day 
6 patients; 
median age:5 
years  
(age range: 2-
12). 
36 weeks Reduction in seizure 
frequency in 4/6 
patients (of 25% -
100%). The percentage 
of seizure-free days 
increased in 3/4 of these 
patients. In 2/6 patients, 
no lteration of seizure 
frequency 
[143] 
 
Open-label, 
single-center 
case series 
TSC and 
refractory 
epilepsy 
Sirolimus 
1 mg/m2/d.  
then adjusted  
to trough blood  
levels of 
4-10 ng/mL  
7 patients; 
median age: 6 
years (age 
range: 3-17). 
median 
duration:  
18 months  
(range: 6-36 
months) 
1 patient had >90% 
reduction, 4 had 50%-
90% reduction, and 2 
had <50% reduction 
[146] 
 
Case study SEGAs 
associated 
with TSC 
Everolimus 
5 mg/m2/day 
1 patient; 
13.5-year-old 
girl 
 
12 days Seizure aggravation [147] 
Prospective, 
double-blind, 
parallel-group, 
placebo-
controlled, 
multicenter 
phase 3 
(EXIST-1) 
SEGAs 
associated 
with TSC 
Everolimus 
4.5 mg/m2/day 
then adjusted to 
attain a blood 
concentration of 
5-15 ng/mL. 
8 patients; 
children under 
the age of 3 
35 months  
(range:33-38 
months) 
 
Cessation of seizures in  
1 patient, 
significant (at least a 
50% ) reduction in the 
number of seizures in  2 
patient 
[142] 
Case report TSC-
associated 
epilepsy 
with 
refractory 
generalized 
seizures 
Everolimus 
5 mg/day  
1 patient; 
13-year-old girl 
1.5 year  
 
Reduction in seizure 
frequency from clusters 
of two or three daily to 
one every 2 to 
4 weeks 
[149] 
 
Randomized, 
blinded, lacebo 
controlled, 
phase III trial 
TSC 
associated 
refractory 
seizures 
Everolimus 
titrated from 3 
to 7 ng/mL and 
also from 9 to 
15 ng/mL and 
placebo 
Male or female 
between the 
ages of 2 and 65 
years 
 This study is currently 
recruiting participants 
Novartis 
Pharmaceutic
als 
EXIST-1 = EXamining everolimus In a Study of TSC; SEGA = Subependymal Giant cell Astrocytoma; TSC = Tuberous Sclerosis 
Complex 
 
 
4. Conclusions 
Epilepsy represents one of the oldest and most prevalent neurological disorders. Currently available 
treatments are effective but provide only symptomatic management of the disease, and an unmet 
need exists for a rational therapy that targets the etiology of epilepsy [2,139]. Understanding 
epileptogenesis, the process by which a normal brain becomes epileptic, may help identify 
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molecular targets for drugs that could prevent epilepsy. To date, the mTOR pathway represents 
perhaps, the most promising molecular target for producing a better understanding and treatment of 
this disease. The first favorable point in this regard, is the availability of a number of already 
marketed drugs acting on this target; such drugs (i.e. rapamycin, everolimus etc) are already used 
clinically for other conditions (e.g. as immunosuppressants in kidney transplantation, in treatment 
of advanced renal carcinoma and breast cancer). 
Different preclinical data confirm that mTOR dysregulation may play a pathogenetic role in the 
epileptogenesis of different forms of epilepsy, and that mTOR inhibition may prevent epilepsy 
development, especially in genetic mTORopathies. mTOR inhibitors show efficacy in treating some 
genetic forms of epilepsy (e.g. TSC and WAG/Rij rats) but also possess antiepileptogenic effects in 
preclinical models. The potential inhibition of mTOR as a therapeutic strategy for preventing 
epileptogenesis is therefore promising and may be applicable not only to TSC, but also to other 
forms of epilepsy. These findings are starting to be translated into the clinical arena; successful 
anticonvulsant effects of both rapamycin and everolimus have been reported in individuals with 
focal-onset seizures in the context of TSC. While several studies with TSC mouse models suggest 
that mTOR inhibitors have antiepileptogenic properties for preventing epilepsy, clinical 
antiepileptogenic drug trials are difficult to conduct and have not yet been attempted with mTOR 
inhibitors. Some controversial results with mTOR inhibitors also exist and while it is clear that the 
mTOR pathway might be a good target candidate, some drawbacks of ‘general’ mTOR inhibition 
must still be considered and more studies are warranted (ideally with more selective drugs), before 
full clinical translation of mTOR targeting can result. In particular, the time-window, duration and 
dosages to be used in prevention of epileptogenesis are still far from being clearly identified. On the 
other hand, mTOR inhibitors possess only a very low efficacy in preclinical animal models of 
seizures/epilepsy and therefore, their effectiveness in stopping seizures is probably very limited 
and/or in any case, it might require time before some kind of effectiveness can be observed; 
generally, a few days of treatment are necessary to observe an antiseizure effect if any. As most of 
 23 
the beneficial effects of mTOR inhibition might cease after drug discontinuation, a life-long 
treatment might be necessary. The effect of long-term mTOR inhibition on developing brain 
structures and functions is still not fully understood. Despite several drugs acting on mTOR that are 
already currently available (both considering marketed and experimental drugs), none of these 
agents has selectivity for the CNS, which obviously underlies the appearance of peripheral side 
effects that might limit dosages and therefore efficacy. The search for more selective agonists 
targeting specific effectors of the mTOR pathway can lead to the discovery of better drugs to treat 
epilepsy. As mentioned above, clinical trials are currently undergoing for both everolimus and 
rapamycin in epilepsy. The results of these trials will indeed shed light on the possibility to use such 
molecules in TSC patients; however, this will only be an initial step, which will need further 
clinical trials to understand the possible use of mTOR inhibitors in other clinical situations with 
patients at risk of epilepsy development (e.g. traumatic brain injury). 
Interactions between mTOR inhibitors and available antiepileptic drugs are not fully known and 
will have to be analyzed. The role of mTOR inhibitors in epilepsy treatment still needs further 
research and an extension of clinical trials to non-TSC epilepsy syndromes. Further clinical studies 
could help to clarify the clinical efficacy, dosage and safety profile of mTOR inhibitors in epilepsy 
and epileptogenesis. Despite these limitations, recent developments in mTOR pathway modulation 
open up new perspectives for future therapy of epilepsy and mTOR inhibitors represent a promising 
therapeutic option for the treatment of epilepsy.  
In conclusion, as in the case of many other diseases, we feel that the mTOR pathway represents a 
great opportunity for future novel drug development in epilepsy therapeutics; the actual available 
data with mTOR inhibitors, both clinical and pre-clinical are intriguing and highly support future 
experiments. Finally, a very important task will be that of developing new mTOR inhibitors with a 
higher selectivity for the central nervous system (CNS) and a better safety profile. 
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The mTOR Complexes and Signaling Pathways 
The mammalian target of rapamycin (mTOR) is a protein serine-threonine kinase that belongs to 
the phosphoinositide 3-kinase (PI3K)-related kinase family [1,2]. Rapamycin (also known as 
sirolimus) is a macrolide antibiotic molecule extracted from the mycelium of the Easter Island 
(Rapa-Nui) soil-dwelling bacterium Streptomyces hygroscopicus. This macrolide, through its 
specific ability to inhibit mTOR, is mainly used as an antifungal, immunosuppressant, and 
anticancer agent [3]. mTOR is activated by phosphorylation in response to several modulators  such 
as growth factors, mitogens and hormones. The molecular factors and downstream target signaling 
molecules associated with the mTOR pathway are numerous and complex. The signal transduction 
mechanisms linked to mTOR have been studied extensively and have been related to a huge 
spectrum of fundamental biochemical and physiological processes, such as metabolism, cell 
growth, proliferation, differentiation, longevity, apoptosis, and autophagy [4]. In mammalian cells, 
the functions of mTOR are mediated through two mTOR heteromeric and functionally distinct 
protein complexes: mTORC1 and mTORC2. These complexes are formed by mTOR and several 
proteins, two of which are in common to both mTORC1 and 2: one is the mammalian lethal with 
Sec13 protein 8 (mLST8, also known as GβL), a positive regulator and the other named DEPTOR 
(DEP-domain containing mTOR-interacting protein) is a physiological negative regulator. 
mTORC1 has two other associated proteins, the positive regulator named RAPTOR (regulatory-
associated protein of mTOR) and PRAS40 (proline-rich AKT substrate of 40 kDa) or AKTS1 
(AKT1 substrate), which shows a suppressive action. mTORC2 shows three components in 
common with mTORC1 and three specific proteins: RICTOR (rapamycin-insensitive companion of 
mTOR), which plays an important role also for the interaction between mTORC2 and tuberous 
sclerosis complex 2 (TSC2), a direct activator of this complex [5]; mSIN-1 (mammalian stress-
activated protein kinase interacting protein) fundamental for its ability to phosphorylate AKT [6], 
Supplementary Material
and PROTOR-1 (protein observed with RICTOR-1), which is required for efficient mTORC2-
mediated activation of SGK-1. Moreover, PROTOR-1 is able to bind RICTOR [7].  
In particular, mTORC1 rapamycin-sensitive complex, the better characterized of the two 
complexes, is fundamental in controlling a wide variety of cellular processes including protein 
synthesis, autophagy, cell cycle and microtubule dynamics. Conversely, mTORC2, a rapamycin-
insensitive complex, regulates both the development of cytoskeleton and cell survival.  
Recent findings demonstrated that mTORC2 plays a role in genome stability maintenance under 
oxidative and replicative stress [8] showing a different sensitivity to rapamycin, which inhibits 
mTOR through the binding to FKBP12 (FK 506-binding protein of 12 KDa). In particular, it has 
been demonstrated that although mTORC2 is insensitive to acute rapamycin exposure, it can be 
modulated by prolonged rapamycin treatment [9]. 
 
Upstream of mTOR Signaling 
mTOR pathway is activated by mitogens, brain-derived neurotrophic factor (like BDNF) or 
hormones (such as insulin and insulin-like growth factor 1 (IGF1), vascular endothelial growth 
factor (VEGF) and ciliary neurotrophic factor (CNTF), glutamate, and guidance molecules [10-12]. 
All these input signals that positively or negatively control mTORC1 activity are mediated by the 
activation of receptor tyrosine kinase (RTKs) and converge on tuberous sclerosis complex, 
comprised of TSC1 (harmatin) and TSC2 (tuberin). TSC1/2 is a GTPase activating protein (GAP) 
for the small G protein Rheb (Ras homolog enriched in brain) and Rhes (a form of Rheb mainly 
expressed in the brain) [13,14]. The phosphorylation of TSC1/2 occurs through activation of 
mTORC1 by channel receptors, GPCRs, RTKs and cytokine receptors via protein kinases (e.g. Akt 
and ribosomal S6 kinase (RSK) [15]. As a result, TSC1/2 complex results inactivated and induces 
an increase of Rheb-GTP, that is an important activator of mTORC1 [16]. Rheb-GTP activates 
mTORC1 through interacting with mTOR [17]. One of the most important upstream modulators of 
mTOR activity is the heterodimer TSC1/2, whose activity can inhibit mTOR. Only TSC2 has 
GTPase-activating properties; however, both TSC1 and TSC2 are required for the function of this 
heterodimer. A small G protein Rheb (Ras homolog enriched in brain) is a direct downstream target 
of TSC1/2 and a positive regulator of mTOR function, which induces a conformational change of 
mTOR that results in activation and phosphorylation of protein effectors [18]. More recently, a third 
component (TBC1D7) collaborating with TSC1/2 in the activation of Rheb has been identified 
[19,20]. Rheb-GTP activates the mTORC1 complex interacting with Raptor. In addition, Rheb 
regulates 4EBP1 binding to mTORC1 reducing mTOR activity through the control of mTOR 
association with mTORC1 by FKBP38. The latter is structurally linked to an endogenous inhibitor 
of mTOR named FKBP12. 
The TSC1/2 complex receives inputs from different signal-transduction pathways [21], predictably, 
many of the molecules that bind or regulate the TSC1/2 complex can also regulate mTOR, among 
them there is the serine/threonine kinase Akt. This kinase is activated by growth factors such as 
insulin or epidermal growth factor (EGF), through both phosphorylation and the lipid products of 
phosphatidylinositol 3-kinase (PI3K). Once activated, Akt then directly phosphorylates and reduces 
the activity of TSC2 and, therefore, increases signaling through Rheb and mTOR [22-24]. 
Mutations (including nonsense, missense, insertion, and deletion) of TSC1 or TSC2, causing loss of 
TSCs function produce an overactivation of mTORC1 and brain diseases. TSC2, and its 
phosphorylation, induces both activation and inactivation of mTORC1 depending on the phospho-
acceptor amino acid residues. Phosphorylation of TSC2 (in particular at Thr1462) by Akt and by 
MAPK (at Ser664) (akaErk) inhibits TSC1/2 activity thus activating mTORC1, whereas 
phosphorylation of TSC2 (at Ser1345 and Thr1227) by AMP-activated protein kinase (AMPK) 
enhances TSC1/2 activity leading to the suppression of mTORC1 activity [23,25]. Hence, AMPK 
and Akt exert opposite regulations of TSC2 activity. AMPK is able to inhibit mTORC1 through the 
phosphorylation of Raptor [26]. 
In neurons, mTOR activity is also modulated by some neurotransmitters such as glutamate and 
dopamine receptors [27,28]. In particular, G-protein coupled receptors (GPCRs) such as, 
metabotropic glutamate, μ-opioid and cannabinoid receptors, activate mTORC1 in neurons [29-31]. 
Because GPCRs are known to transduce signals to Akt and/or MAPK, mTORC1activation triggered 
by these ligands seems to inhibit TSC2. In particular, group I mGluRs are coupled to mTOR-
p70S6K and ERK1/2-p70S6K pathways in striatal and hippocampal synaptoneurosomes [30] and 
hippocampal CB1 cannabinoid receptor (CB1R) activation modulated the mammalian target of 
rapamycin (mTOR)/p70S6K pathway inducing amnesic effects [31]  
 
Downstream of mTOR Signaling 
Many substrates have been identified as mTOR downstream effectors mediating several cellular 
responses. p70 ribosomal S6 protein kinases 1 and 2 (p70S6K1/2) and eukaryotic initiation factor 
4E (eIF4E)-binding proteins  (4E-BPs) are the best-characterized substrates for mTORC1 regulating 
translation [16,32]. 
The binding of 4E-BPs to elongation factor 4E binding protein 1 (eIF4E) inhibits the formation of 
the eIF4F complex, required for the initiation of translation [33]. mTOR phosphorylates and 
activates S6K and 4EBPs, suppressing this inhibition and promoting ribosomal biogenesis and 
protein translation [34,35]. Consequently, the protein synthesis is induced by the inhibition of the 
elongation factor 4E binding protein 1 (4EBP1) [32].  
mTORC1 pathway also controls autophagy as a consequence of the inhibition of ULK1 complex 
(Unc51-like kinase 1)/Atg13 (autophagy-related genes 13)/FIP200 (focal adhesion kinase family-
interacting protein of 200 kDa) [36]. mTOR controls the cellular response to hypoxia regulating the 
transcription/translation of hypoxia inducible factor 1α (HIF1α) [37]. HIF1α-mediated mechanisms 
are important for angiogenesis following hypoxia and have been involved in different 
neurodegenerative disease but also in stroke and neonatal hypoxic-ischemic injury [38]. Among the 
transcription factors regulated by mTORC1 are the sterol-response binding proteins (SREBPs), 
which regulate lipogenesis [39,40]. 
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